News | Proton Therapy | August 08, 2019

MD Anderson to Expand Proton Therapy Center

$159 million investment will double facility’s size, allowing more patients access to care

MD Anderson to Expand Proton Therapy Center

The MD Anderson Proton Therapy Center expansion is expected to be completed in 2023. Rendering courtesy of Stantec.

August 8, 2019 ― The University of Texas MD Anderson Cancer Center unveiled plans to expand its Proton Therapy Center during a groundbreaking ceremony. The expansion will more than double the center’s size to more than 160,000 square feet – almost the size of three football fields – allowing more patients greater access to the most advanced and precise form of radiation therapy.

The estimated completion of the new building is November 2023. The $159 million expansion will be led by Gilbane Building Co. and will increase the center size to include a total of eight radiation therapy machines that rotate 360 degrees around a patient to deliver a proton beam to the exact area intended for treatment. The new machines, developed by Hitachi, will deliver intensity-modulated proton therapy (IMPT), the most precise form of image-guided radiation therapy (IGRT) available. The expansion also will include an additional synchrotron, the massive accelerator that creates the proton beam, as well as rooms with improved design for a better patient experience.

“For over a decade, MD Anderson has led the world in the field of proton therapy,” said Peter WT Pisters, M.D., president. “Our physicians and international cancer experts continue to push the boundaries to provide the most innovative care to our patients, and now we are working to provide increased access to that care so even more people can potentially benefit from this important treatment option.”

Proton therapy is an advanced type of radiation treatment that uses a beam of protons to deliver radiation directly to the tumor, destroying cancer cells while sparing healthy tissue. Protons enter the body with a low radiation dose, stop at the tumor, match its shape and volume or depth, and deposit the bulk of their cancer-fighting energy precisely at the tumor.

This therapy currently is used to treat a number of cancers in adult and pediatric patients, including prostate, lung, head and neck, liver, esophagus, brain and lymphoma, a cancer of the lymphatic system.

“This expansion is critical for patients who need access to proton therapy,” said Steven J. Frank, M.D., medical director of the Proton Therapy Center. “Our center has been operating at capacity, treating patients 20 hours a day, five days a week. Doubling our size will mean not only that we can treat more patients, but that we can do so using the very latest technology while achieving remarkable efficiency.”

Since opening in 2006, MD Anderson’s Proton Therapy Center has treated more than 9,300 patients from the United States and across the world within its current 73,500-square-foot facility. In 2018, MD Anderson treated 819 patients with proton therapy, a nearly 11 percent increase from 2017. Currently, 38 percent of patients are treated for head and neck cancers, but the center also sees numerous patients for prostate, lung, liver and brain cancers, as well as a range of pediatric cancers.

“As more patients become eligible for proton therapy, we want to make sure that those who need access to protons have the opportunity to receive them,” said Pisters. “This expansion will aid us in our efforts to provide the most-effective treatment for each patient, based on their specific disease.”

For more information: www.mdanderson.org

Related Content

Eclipse v16 has received CE mark and is 510(k) pending
News | Proton Therapy | April 06, 2020
April 6, 2020 — Driven by its Intelligent Cancer Care approach in developing new solutions that use advanced technolo
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...
Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group

Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group. Racial/ethnic groups are mutually exclusive. Data for the non‐Hispanic American Indian/Alaska Native (AI/AN) population are restricted to Indian Health Service Purchased/Referred Care Delivery Area (PRCDA) counties. API indicates Asian/Pacific Islander. Chart courtesy of ACS Journals 

News | Radiation Oncology | March 16, 2020
March 16, 2020 — The Ann...